$VOGX

Vogenx IPO: 6.25M shares at $11–$13 puts $75M Nasdaq deal days away

Vogenx, Inc. filed a second S-1 amendment with the SEC on Aug. 10, 2026, setting an IPO price range of $11 to $13 for 6.25 million shares. The company said the deal would raise $75 million at the midpoint. JonesTrading is sole underwriter, and the proposed Nasdaq ticker is VOGX.

Original reporting
Published Aug 10, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vogenx IPO: 6.25M shares at $11–$13 puts $75M Nasdaq deal days away — source image
Decision brief

The 30-second read

$VOGXNeutralMed
01

Why it matters

The key tradable element is reduced uncertainty around deal structure and the likelihood of final pricing soon, which can affect IPO allocation expectations and pre-debut sentiment.

02

Market read

Late-stage IPO filing mechanics for Vogenx point to imminent pricing, creating a near-term catalyst for IPO-related positioning and volatility.

03

What to watch

The sole underwriter structure (JonesTrading running the book) increases execution risk; without disclosed book-building indications, traders should not assume the midpoint is achievable.

Relevance 7/10Novelty 7/10Timing: IPO pricing likely imminent after the Aug 10 S-1 amendment

Background

Vogenx is advancing through the IPO process with a second S-1 amendment that locks in a specific offering range and share count.

Company-level read

Ticker impact

$VOGXNeutralMedium confidence
Context

Vogenx filed a second S-1 amendment setting an IPO price range of $11 to $13 for 6.25M shares, with Nasdaq debut imminent.

Expected impact

Higher pre-pricing volatility; direction depends on book-building demand versus the $11 to $13 range.

Evidence & confidence

The article discloses concrete IPO mechanics (range, share count, underwriter structure) but no demand metrics or final offer price, limiting directional certainty.

Market effects

Adds another small-cap IPO supply into the Nasdaq pipeline, which can marginally affect risk appetite for pre-revenue or early-stage growth listings.

Primarily US-focused via Nasdaq debut expectations.

Limited, as the disclosure is company-specific and not a cross-market macro event.

Counterpoint

A stated range does not guarantee strong demand; if investor appetite is weak, the final price could land near the low end, pressuring first-day performance.

Key entities

  • Vogenx, Inc.

    Company filing the second S-1 amendment with an IPO price range of $11 to $13 and 6.25M shares.

  • JonesTrading

    Sole underwriter running the book for the proposed Nasdaq IPO under the ticker VOGX.

  • SEC

    Receives the S-1 amendment filing that provides the authoritative offering terms.

Related articles

$LTGOMedAI 8/10

Latigo Bio’s IPO Lands $346M for Pipeline of Non

Latigo Biotherapeutics IPO raised $346M to fund its non-opioid pain pipeline, including LTG-001, a NaV1.8 blocker targeting Phase 3. In a Phase 2b abdominoplasty trial (343 patients), both doses reduced pain vs placebo; only the high dose cut opioid rescue use. Latigo says meaningful relief began in 52 minutes. Shares began trading on Nasdaq as LTGO.

$HOODMed

Robinhood’s new venture fund comes with a bold risk label

Robinhood is launching Robinhood Ventures Fund II (ticker RVII), a business development company offering 8 million shares at $25 each starting Aug. 13. The fund plans to raise $200 million, led by Goldman Sachs. It invests in Y Combinator-linked seed startups and charges a 2% management fee plus a 20% incentive fee, with estimated annual expenses of 4.18%. The prospectus labels the offering speculative and warns of potential discounts to net asset value.